Literature DB >> 26778176

Epileptic encephalopathy: Use and misuse of a clinically and conceptually important concept.

Katherine B Howell1,2,3, A Simon Harvey1,2,3, John S Archer4,5,6.   

Abstract

The term epileptic encephalopathy (EE) denotes a process by which epileptic activity adversely affects brain function over and above the underlying etiology. Underlying mechanisms are poorly understood, but recent studies demonstrate that seizures and interictal epileptiform discharges can disrupt distributed neural networks that underpin cognitive functions, both temporarily and permanently. EE is just one of a number of factors that can affect development in epilepsy. The presence and relative contribution of EE to cognitive impairment is often difficult to separate from that of the underlying etiology or even effects of antiepileptic medication (AEM). This difficulty has led to the increasing use of the term EE to encapsulate "severe" epileptic syndromes, or etiologies associated with severe epilepsy and intellectual disability (ID), regardless of evidence that the epileptic process has impacted cognition. The use of the term EE in the literature to describe both the process of cognitive impairment by epileptic activity and as a category for severe epilepsy syndromes is creating confusion. We propose that use of the term EE be restricted to the central concept of a pervasive epileptic process disrupting development, and that the use of EE as a classifier be avoided. A different term is needed to encapsulate the broad and heterogenous group of patients with severe epilepsy and ID, for which the mechanisms may be unknown but are often closely related to the underlying genetic, metabolic, or structural etiology. An improved understanding of the mechanisms by which EE develops is of critical importance, potentially leading to identification of biomarkers for early detection and treatment. Wiley Periodicals, Inc.
© 2016 International League Against Epilepsy.

Entities:  

Keywords:  Epileptic encephalopathy; Lennox-Gastaut syndrome

Mesh:

Year:  2016        PMID: 26778176     DOI: 10.1111/epi.13306

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  13 in total

1.  Epileptic Encephalopathy in Infants and Children.

Authors:  Carl E Stafstrom; Eric M Kossoff
Journal:  Epilepsy Curr       Date:  2016 Jul-Aug       Impact factor: 7.500

2.  Altered gene expression profile in a mouse model of SCN8A encephalopathy.

Authors:  Ryan S Sprissler; Jacy L Wagnon; Rosie K Bunton-Stasyshyn; Miriam H Meisler; Michael F Hammer
Journal:  Exp Neurol       Date:  2016-11-09       Impact factor: 5.330

Review 3.  Epileptic Encephalopathies-Clinical Syndromes and Pathophysiological Concepts.

Authors:  Markus von Deimling; Ingo Helbig; Eric D Marsh
Journal:  Curr Neurol Neurosci Rep       Date:  2017-02       Impact factor: 5.081

4.  Evolution and course of early life developmental encephalopathic epilepsies: Focus on Lennox-Gastaut syndrome.

Authors:  Anne T Berg; Susan R Levy; Francine M Testa
Journal:  Epilepsia       Date:  2018-09-26       Impact factor: 5.864

5.  Cognition, Behavior, and Psychosocial Effects of Seizures in the Developing Brain.

Authors:  Katerina Lin; Carl E Stafstrom
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 6.  Network science for the identification of novel therapeutic targets in epilepsy.

Authors:  Rod C Scott
Journal:  F1000Res       Date:  2016-05-16

Review 7.  Clinical Spectrum of KCNA1 Mutations: New Insights into Episodic Ataxia and Epilepsy Comorbidity.

Authors:  Kelsey Paulhus; Lauren Ammerman; Edward Glasscock
Journal:  Int J Mol Sci       Date:  2020-04-17       Impact factor: 5.923

8.  Efficacy and safety of levetiracetam in children with epilepsy: protocol for an umbrella review of systematic reviews and meta-analyses of randomised controlled trials.

Authors:  Jing Gan; Dan Ma; Tao Xiong
Journal:  BMJ Open       Date:  2019-07-10       Impact factor: 2.692

Review 9.  Benign and severe early-life seizures: a round in the first year of life.

Authors:  Piero Pavone; Giovanni Corsello; Martino Ruggieri; Silvia Marino; Simona Marino; Raffaele Falsaperla
Journal:  Ital J Pediatr       Date:  2018-05-15       Impact factor: 2.638

10.  Survival of a male patient harboring CASK Arg27Ter mutation to adolescence.

Authors:  Konark Mukherjee; Paras A Patel; Deepa S Rajan; Leslie E W LaConte; Sarika Srivastava
Journal:  Mol Genet Genomic Med       Date:  2020-07-21       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.